Bausch + Lomb announced that the US Centers for Medicare and Medicaid Services (CMS) has issued a permanent, product specific J-Code J3299 “Injection, Triamcinolone acetonide (XIPERE) 1 mg” for Xipere (triamcinolone acetonide injectable suspension), which will become effective for provider billing on July 1, 2022. 

“At Bausch + Lomb, we are committed to bringing new and innovative therapies to market that benefit eye care professionals and the patients they serve. This not only applies to the development of new therapies, but also making these therapies accessible once they become available,” Yolande Barnard, senior vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, said in a company news release. “The issuance of the permanent J-Code will help facilitate access to Xipere for Americans suffering from macular edema associated with uveitis and help streamline the reimbursement process.” 

Xipere was approved by the FDA on October 25, 2021 and is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis, a form of eye inflammation.1,2 It became commercially available in March 2022.  

Physicians interested in attending a Xipere training session can register at https://www.xipere.com/hcp/xipere-training. For more information on Xipere, visit www.xipere.com.